A novel anticancer drug targeting the polo box domain of PLK1

Item Number: 574
Industry: Therapeutic
Category: Oncology
Development Stage: Early Stage
Organisation Type: Government Institute
Country: South Korea
Patent: Korea, PCT
Business Opportunity: Out-Licensing, Collaboration R&D


Development of PPI-based anticancer drug using NCAPG2 which is newly identified PLK1 binding protein and the PBD binding structure of PLK1

Features & Contact

Sign in and you'll be able to send enquiries about this item, view full details and save it